Pfizer Takes First Small Step Into Longevity Field With Gero Collaboration
A Milestone For Field, Says Biotech
Executive Summary
Interest in longevity and anti-aging is gathering momentum, and Pfizer has dipped its toe in the water with an early-stage drug discovery partnership.
You may also be interested in...
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.